
Synthesis and Biological Evaluations of Some New Oxadiazole-piperidine Hybrid Derivatives as Antioxidant Agents

Mohammed M. Abdullah Al-Ghorbani^{1,2}*

¹Department of Chemistry, Ulla Science and Arts College, Taibah University, Kingdom of Saudi Arabia ²Department of Chemistry, University of Thamar, Yemen

ABSTRACT A series of some new 1,3,4-oxadiazole-2-thiol derivatives (**6a-h**) containing cyclic secondary amine such as piperidine ring was expeditiously synthesized by alkylation of 1,3,4-oxadiazol-2-thiol derivatives with chloroethyl piperidine hydrochloride. The 1,3,4-oxadiazole-2-thiols were effectively synthesized by cyclization reaction of acid hydrazide derivatives with carbon disulfide. The target compounds **6a-h** were preliminarily screened for *in vitro* antioxidant activities using various *in vitro* antioxidant assays including 2,2'-diphenyl-1-picrylhydrazyl, nitric oxide, and hydrogen peroxide methods. The results showed that the compounds exhibited promising antioxidant property in the three methods at 50, 75, and 100 μM. Among the tested compounds, the compounds **6a** and **6b** having chloro substituent in the benzene ring displayed greater radical scavenging activity.



6a;a: R=4-Cl, n=1 is **the** higher radical scavenging activity than others substitutents

KEYWORDS Oxadiazole–piperidine, Synthesis, Antioxidant activity.

INTRODUCTION

Reactive oxygen species (ROS) are highly reactive molecules that encompass singlet oxygen superoxide anion radical, hydrogen peroxide (${\rm H_2O_2}$), (${\rm ^1O_2}$), and hydroxyl radical (${\rm ^1OH}$) that could be generated by normal metabolic process or from exogenous elements. [1]

ROS has various pathological processes and can motive many diseases, which include atherosclerosis, cardiovascular disease, diabetes, and cancer.^[2] Furthermore, ROS is related to qualitative decay of ingredients, which cause toxicity, rancidity, and destruction of critical biochemical pieces in

physiologic metabolism.^[3] Hence, it is significant to develop effective harmless antioxidants to scavenge free radicals inside the human body.

ISSN (Print) : 0971-1627 ISSN (Online) : 2456-4311

1,3,4-Oxadiazole and its derivatives have a high potential for biological activity and have drawn much attention during the present decades.^[4-7] They have a wide range of pharmacological applications including potential antitumor and antioxidant activities.^[8-10]

The literature survey has revealed that the structural modification of [1,3,4]-oxadiazole-2-thiols by the introduction of nitrogen-containing heterocycles can further enhance the antioxidant activity of candidate compounds. [11,12]

*Corresponding author: E-mail: mghorbani@taibahu.edu.sa

Published & Hosted by :

Journals

www.connectjournals.com


The piperidine analogs are an attractive drug template because of its significant biological applications as antioxidant, antihistaminic, anti-inflammatory, fungicidal, bactericidal, anticancer, analgesic, CNS stimulant, and depressant activities. [13-16] Thus, piperidine moiety-containing molecules play an essential role in the field of medicinal chemistry.

Based on the above observations, it was thought worthwhile to prepare new compounds that contain oxadiazole and piperidine ring systems with a view to produce promising antioxidant agents. Therefore, several hybrids were synthesized and investigated for the antioxidant activities using several determination methods 2,2'-diphenyl-1-picrylhydrazyl (DPPH), nitric oxide (NO), and H₂O₂ radical scavenging assays.

RESULTS AND DISCUSSION

Chemistry

The general synthetic route for the preparation of the title compounds **6a-h** is illustrated in **Scheme 1**. Initially, phenoxyacetic/butyric acid ethyl esters **3a-h** were obtained by the condensation of substituted phenols 1a-e with 2a-b in the presence of anhydrous K₂CO₂ and confirmed by the disappearance of OH stretching and appearance of carbonyl stretching band for the ester group at 1733-1742 cm⁻¹ in the infrared (IR) absorption spectra. The proton NMR observations revealed that broad singlet for OH proton was disappeared and a triplet and quartet for CH, and CH₂ protons at 1.32–135 and 4.21–4.33 δ , respectively, were appeared.^[7] Compounds **3a-h** were treated with the slight excessive equivalent amount of hydrazine hydrate to produced phenoxyacetic/butyric acid hydrazide derivatives 4a-h, and the chemical structure of 4a-h was established by the appearance of NH₂ stretching band of amide at 3309– 3323 cm⁻¹ in the IR spectra. In proton NMR, the appearance of NH, and NH protons at 3.83-3.91 and 8.40-8.46 δ , respectively, and disappearance of triplet and quartet peaks for CH₃ and CH₃ protons have confirmed the formation



Scheme 1: Synthesis of 1-[2-(5-phenoxymethyl-[1,3,4] oxadiazol-2-ylsulfanyl)-ethyl]-piperidines (6a-h)

of the acid hydrazide derivatives **4a-h**. 1,3,4-oxadiazol-2thiols **5a-h** were prepared by cyclization of acid hydrazide derivatives 4a-h with carbon disulfide in the presence of KOH which were clearly evident with the disappearance of carbonyl and NH, stretching band in the IR spectra. The appearance of SH proton at $10.72-10.76 \delta$ and the disappearance of NH, and NH protons of amide in the NMR spectra also confirmed the product. Finally, compounds 5a-h were subjected to alkylation with chloroethyl piperidine hydrochloride in the presence of anhydrous K,CO, to afford the title compounds 6a-h. This was supported by the disappearance of SH stretching in the IR spectra as well as by the disappearance of SH proton and appearance of methylene protons of piperidine at 1.54-1.58 and 2.36-2.41 δ in the NMR spectra. Further, the mass spectral data of these compounds displayed molecular ion peaks which confirmed their molecular weights.

Biology

Oxadiazole-piperidine derivatives 6a-h were tested for the antioxidant property by DPPH, NO, and H₂O₂ radical scavenging assays using ascorbic acid as standard antioxidant. The experiments were carried out at three different concentrations in triplicates; the results are expressed as mean ± standard deviation (SD) and were summarized in **Table 1-3**. The structure-antioxidant activity relationship of the synthesized compounds revealed that compounds 6a-h exhibited promising antioxidant property in the three methods at 50, 75, and 100 µM concentrations but showed less activity compared with the ascorbic acid. The scavenging effect gradually increases with the increasing concentrations of test compounds. Among the compounds tested, the compounds 6a and 6b having chloro substituent in the benzene ring displayed greater radical scavenging activity. The compounds 6c, 6d, and 6e having two nitro and bromo substituents in the benzene ring showed moderate radical scavenging abilities, while 6f, 6g, and 6h having methyl and methoxy substituent, respectively, in the benzene ring showed poor radical scavenging abilities in comparison with the standard antioxidant ascorbic acid. However, compound 6a having a chloro substituent exhibited higher radical scavenging activity than **6b** which has the same group, but it has single CH, while 6b has three CH, Remarkably, compounds 6c, 6d, 6g, and 6h which displayed moderate activity showed less activity with increasing substitutions of CH₂. Hence, increasing aliphatic chain length in compounds **6a-h** would obviously decrease the scavenging efficacy of the compounds. Moreover, due to electron-donating substituents of methoxy and methyl, stereochemical factors of ortho substitution of methyl substituent might cause for lower activity associated with the compounds 6g, 6h, and 6f.

EXPERIMENTAL SECTION

Melting points were determined on a Thomas Hoover capillary melting point apparatus with a digital thermometer. IR spectra were recorded as Potassium bromide Discs on Shimadzu Fourier-transform infrared (FT-IR) 8300 spectrometer. ¹H-NMR spectra were recorded on Bruker spectrophotometer at 400 MHz in CDCl₃; values (δ) are given

Table 1: DPPH radical scavenging ability of the compounds 6a-h relative to the standard antioxidant ascorbic acid

Compound	% radical scavenging activity		
	$50 \mu g/mL$	$75~\mu g/mL$	$100~\mu\text{g/mL}$
6a	60.24±1.20	63.55±1.24	65.81±1.61
6b	55.78 ± 1.14	58.75±1.47	60.44 ± 1.08
6c	36.68 ± 0.63	37.36±0.86	39.36±1.46
6d	40.13±0.68	41.32±0.67	44.52±1.15
6e	51.84 ± 0.86	55.92±1.42	59.87±1.61
6 f	24.15±1.17	27.86±1.21	29.81±1.26
6 g	26.84±0.71	27.50±0.77	29.39±1.37
6h	24.12 ± 0.56	25.93±0.78	27.28±1.15
Ascorbic acid	77.15 ± 0.45	80.95±0.39	83.82±0.81

Values were the means of three replicates±S.D. SD: Standard deviation, DPPH: 2,2'-diphenyl-1-picrylhydrazyl

Table 2: NO radical scavenging ability of the compounds 6a-h relative to the standard antioxidant ascorbic acid

4557575 4574					
Compound	% radical scavenging activity				
	50 μg/mL	$75 \mu g/mL$	$100~\mu g/mL$		
6a	64.56±0.98	67.55±1.13	68.81±1.56		
6b	56.74 ± 0.87	57.75±0.94	59.44±1.28		
6c	41.51±0.74	43.34±0.85	44.79±1.59		
6d	52.77±0.65	54.56±0.69	56.13±1.07		
6e	56.67±0.81	58.92±1.21	59.87±1.53		
6f	$28.85{\pm}1.05$	29.65±0.99	30.98±1.34		
6 g	27.73 ± 0.89	29.17±0.81	32.46±1.39		
6h	26.55±0.60	27.64±0.75	28.35±1.25		
Ascorbic acid	78.23 ± 0.17	81.46±1.37	82.79 ± 0.80		

Values were the means of three replicates±S.D. SD: Standard deviation, NO: Nitric oxide

Table 3: ${
m H_2O_2}$ radical scavenging ability of the compounds 6a-h relative to the standard antioxidant ascorbic acid

ascorbic acid					
Compound	% radical scavenging activity				
	50 μg/mL	75 μg/mL	100 μg/mL		
6a	61.34±1.18	63.23±1.43	64.18±1.44		
6b	52.74±1.07	54.68±1.17	56.12±1.31		
6c	38.75±1.16	39.19±1.06	41.±1.35		
6d	47.19±0.89	48.56±0.86	50.19 ± 1.25		
6e	51.04±1.22	53.82±1.15	55.87±1.29		
6f	23.66±1.30	24.16±1.09	27.56±1.39		
6 g	25.99±1.11	27.56±0.98	30.54 ± 1.28		
6h	19.78±0.93	22.54±1.11	24.88±1.32		
Ascorbic acid	77.68±0.51	79.27±1.29	83.16±0.44		

Values were the means of three replicates \pm S.D. SD: Standard deviation, H_3O_s : Hydrogen peroxide

in parts per million (ppm) downfield from tetramethylsilane (TMS) as internal reference standard. ¹³C-NMR spectra were recorded using the same spectrophotometers that used

for recording¹ H NMR. Mass spectra were obtained with a VG70-70H spectrophotometer. The elemental analysis of the compounds was performed on a PerkinElmer 2400 Elemental Analyzer.

Chemistry

General synthetic procedure for phenoxyacetic/butyric acid ethyl ester derivatives (3a-h)

A mixture of substituted phenols 1a-e (0.75 mol) and 2a-b (0.10 mol) in dry acetone (50 ml) with K_2CO_3 (0.10 mol) was refluxed for 10–14 h. The solvent was removed by distillation. The crude was triturated with cold water to remove potassium carbonate and extracted with ether. The ether layer was washed with 10% sodium hydroxide solution followed by water and then dried over anhydrous sodium sulfate and evaporated to afford compounds 3a-h.

(4-Chlorophenoxy)acetic acid ethyl ester (3a)

Yield 90%; FT-IR (cm $^{-1}$): 1738 (C=O); 1 H-NMR (CDCl $_{3}$): δ : 1.35 (t, 3H, CH $_{3}$ of ester), 4.21 (q, 2H, CH $_{2}$ of ester), 5.01 (s, 2H, OCH $_{2}$), 7.32 (d, 2H, Ar-H), 7.49 (d, 2H, Ar-H); liquid chromatography—mass spectrometry (LC-MS) m/z 214 (M $^{+}$), 216 (M+2). Anal. Calcd. for C $_{10}$ H $_{11}$ ClO $_{3}$: C, 55.96; H, 5.17. Found: C, 55.49; H, 5.27%.

General synthetic procedure for phenoxyacetic acid/butyric acid hydrazide derivatives (4a-h)

Hydrazine hydrate (0.060 mol) was added to the solution of compounds **3a-h** (0.045 mol) in ethanol (25 ml), and the reaction mixture was stirred at room temperature for 4 h. Reaction completion was monitored by thin-layer chromatography using hexane: ethyl acetate (2:1) as the mobile phase and allowed to stand overnight. Formed white crystals **4a-h** were filtered, washed, and after drying recrystallized from ethanol to give **4a-h**.

(4-Chlorophenoxy)acetic acid hydrazide (4a)

Yield 92%; mp 115–117°C; FT-IR (KBr, cm $^{-1}$): 3315 (NH $_2$), 3220 (NH), 1672 (C=O); 1 H NMR (CDCl $_3$): δ 3.85 (d, 2H, NH $_2$), 5.08 (s, 2H, OCH $_2$), 6.88 (d, 2H, Ar-H), 7.27 (d, 2H, Ar-H), 8.40 (t,1H, NH), LC-MS m/z 200 (M $^+$), 202 (M+2). Anal. Calcd. for C $_8$ H $_9$ ClN $_2$ O $_2$: C, 47.89; H, 4.52; N, 13.96. Found: C, 47.78; H, 4.56; N, 14.08%.

General synthetic procedure for 5-phenoxymethyl/propyl-[1,3,4]oxadiazole-2-thiol derivatives (5a-h)

A mixture of hydrazides **4a-h** (4 mmol), carbon disulfide (4 ml), potassium hydroxide (8 mmol), and ethanol (50 ml) was heated under reflux until evolution of hydrogen sulfide was ceased (6–8 h). Afterward, the reaction mixture was cooled to room temperature. The solvent was evaporated at reduced pressure, and cold water was poured and acidified with diluted hydrochloric acid solution to bring the pH between 3 and 4. The precipitate thus separated out was allowed to stand overnight, filtered, washed, and after drying recrystallized from acetone.

5-(4-Chlorophenoxymethyl)[1,3,4]oxadiazole-2-thiol (**5a**) Yield 84%; mp 140–142°C; FT-IR (KBr, cm⁻¹): 1612 (C=N), 2557 (SH), 1164 (C-O-C); ¹H NMR (CDCl₃): δ 5.05

(s, 2H, OCH₂), 6.95 (d, J = 8.80 Hz, 2H, Ar-H), 7.32 (d, J = 8.85 Hz, 2H, Ar-H), 10.72 (s, 1H, SH); LC-MS m/z 242 (M⁺), 244 (M+2). Anal. Calcd. for C₉H₇ClN₂O₂S: C, 44.54; H, 2.91; N, 11.54. Found: C, 44.70; H, 2.82; N, 11.65%.

5-[3-(4-Chlorophenoxy)propyl][1,3,4]oxadiazole-2-thiol (5b) Yield 82%; mp 147-149 °C; FT-IR (KBr, cm⁻¹): 1612 (C=N), 2557 (SH), 1164 (C-O-C); 1 H NMR (CDCl₃): δ 2.37 (m, 2H, CH₂), 2.92 (t, 2H, COCH₂), 4.23 (t, 2H, OCH₂), 6.95 (d, J = 8.80 Hz, 2H, Ar-H), 7.32 (d, J = 8.85 Hz, 2H, Ar-H), 10.72 (s, 1H, SH); LC-MS m/z 270 (M+), 272 (M+2). Anal. Calcd. for C₁₁H₁₁ClN₂O₂S: C, 48.80; H, 4.10; N, 10.35. Found: C, 48.91; H, 4.03; N, 10.25%.

5-(3-Nitrophenoxymethyl)[1,3,4]oxadiazole-2-thiol (**5c**) Yield 84%; mp 142–144°C; FT-IR (KBr, cm⁻¹): 1612 (C=N), 2557 (SH), 1164 (C-O-C); 1 H NMR (CDCl₃): δ 5.11 (s, 2H, OCH₂), 7.23 (d, J = 7.20 Hz, 2H, Ar-H), 7.45 (s, 1H, Ar-H), 7.62 (t, J = 8.80 Hz, 1H, Ar-H), 10.72 (s, 1H, SH); LC-MS m/z 254 (M+1). Anal. Calcd. for C₉H₇N₃O₄S: C, 42.69; H, 2.79; N, 16.59. Found: C, 42.73; H, 2.73; N, 16.57%.

5-[3-(3-Nitrophenoxy)propyl][1,3,4]oxadiazole-2-thiol (5d) Yield 80%; mp 144–146°C; FT-IR (KBr, cm $^{-1}$): 1612 (C=N), 2557 (SH), 1164 (C-O-C); 1 H NMR (CDCl $_{3}$): δ 2.42 (m, 2H, CH $_{2}$), 2.96 (t, 2H, COCH $_{2}$), 4.28 (t, 2H, OCH $_{2}$), 7.23 (d, J = 7.20 Hz, 2H, Ar-H), 7.45 (s, 1H, Ar-H), 7.62 (t, J = 8.80 Hz, 1H, Ar-H), 10.72 (s, 1H, SH); LC-MS m/z 282 (M+1). Anal. Calcd. for C $_{11}$ H $_{11}$ N $_{3}$ O $_{4}$ S: C, 46.97; H, 3.94; N, 14.94. Found: C, 47.17; H, 3.87; N, 15.15%.

5-[3-(4-Bromophenoxypropyl]-[1,3,4]oxadiazole-2-thiol (**5e**) Yield 76%; mp 141–143°C; FT-IR (KBr, cm $^{-1}$): 1612 (C=N), 2557 (SH), 1164 (C-O-C); 1 H NMR (CDCl $_{3}$): δ 2.39 (m, 2H, CH $_{2}$), 2.92 (t, 2H, COCH $_{2}$), 4.27 (t, 2H, OCH $_{2}$), 6.77 (d, J=8.80 Hz, 2H, Ar-H), 7.36 (d, J=8.85 Hz, 2H, Ar-H), 10.72 (s, 1H, SH); LC-MS m/z 315 (M $^{+}$), 317 (M+2). Anal. Calcd. for C $_{11}$ H $_{11}$ BrN $_{2}$ O $_{2}$ S: C, 41.92; H, 3.52; N, 8.89. Found: C, 41.85; H, 3.57; N, 8.80%.

5-o-Tolyloxymethyl[**1,3,4]oxadiazole-2-thiol** (**5f**) Yield 78%; mp 135–137°C; FT-IR (KBr, cm $^{-1}$): 1612 (C=N), 2557 (SH), 1164 (C-O-C); 1 H NMR (CDCl $_{3}$): δ 2.16 (s, 3H, CH $_{3}$), 5.04 (s, 2H, OCH $_{2}$), 6.82 (d, J = 8.80 Hz, 1H, Ar-H), 7.37 (d, J = 7.40 Hz, 1H, Ar-H), 7.54 (t, J = 8.80 Hz, 2H, Ar-H), 10.72 (s, 1H, SH); LC-MS m/z 223 (M+1). Anal. Calcd. for C $_{10}$ H $_{10}$ N $_{2}$ O $_{2}$ S: C, 54.04; H, 4.53; N, 12.60. Found: C, 54.18; H, 4.53; N, 12.51%.

5-(4-Methoxyphenoxymethyl)[**1,3,4]**oxadiazole-**2-thiol** (**5g**) Yield 83%; mp 133–135°C; FT-IR (KBr, cm $^{-1}$): 1612 (C=N), 2557 (SH), 1164 (C-O-C); 1 H NMR (CDCl $_{3}$): δ 3.76 (s, 3H, OCH $_{3}$), 5.06 (s, 2H, OCH $_{2}$), 6.89–7.05 (m, 4H, Ar-H), 10.72 (s, 1H, SH); LC-MS m/z 239 (M+1). Anal. Calcd. for C $_{10}$ H $_{10}$ N $_{2}$ O $_{3}$ S: C, 50.41; H, 4.23; N, 11.76. Found: C, 50.53; H, 4.19; N, 11.66%.

 $\begin{array}{l} \textbf{5-[3-(4-Methoxyphenoxy)propyl]-[1,3,4]oxadiazole-} \\ \textbf{2-thiol (5h)} \ Yield \ 77\%; \ mp \ 148-150^{\circ}\text{C}; \ FT-IR \ (KBr, \ cm^{-1}): \\ 1612 \ (C=N), 2557 \ (SH), 1164 \ (C-O-C); \ ^{1}\text{H} \ NMR \ (CDCl_{_{3}}): \\ \textbf{2}.36 \ (m, 2H, CH_{_{2}}), 2.90 \ (t, 2H, COCH_{_{2}}), 3.76 \ (s, 3H, OCH_{_{3}}), \\ \textbf{4}.22 \ (t, 2H, OCH_{_{2}}), 6.89-7.05 \ (m, 4H, Ar-H), 10.76 \ (s, 1H, Ar-H), 10.76 \ (s, 1H,$

SH); LC-MS m/z 267 (M+1). Anal. Calcd. for $\rm C_{12}H_{14}N_2O_3S$: C, 54.12; H, 5.30; N, 10.52. Found: C, 54.25; H, 5.27; N, 10.61%.

General synthetic procedure for 1-[2-(5-phenoxymethyl-[1,3,4]oxadiazol-2-ylsulfanyl)-ethyl]piperidine derivatives (6a-h)

A mixture of 5-phenoxymethyl/propyl-[1,3,4]oxadiazole-2-thiols (5a-h) (2 mmol), chloroethyl piperidine hydrochloride (5 mmol), and anhydrous potassium carbonate (5 mmol) in ethanol (30 ml) was heated under reflux for 15–24 h. After completion of the reaction, the reaction mixture was cooled down, and excess of solvent was evaporated under reduced pressure. The residue obtained was triturated with cold water to precipitate the desired target compounds 6a-h which were recrystallized from ethanol.

2-((4-Chlorophenoxy)methyl)-5-((2-(piperidin-1-yl) ethyl)thio)-1,3,4-oxadiazole (6a) Yield 70%; mp. 83–85°C; FT-IR (KBr, cm⁻¹): 1333 (C=N), 1272 (C-O-C); ¹H NMR (CDCl₃): δ 1.56 (m, 6H, 2CH₂ of piperidine ring), 2.36 (t, 4H, CH₂NCH₂ of piperidine ring), 2.75 (t, 2H, N CH₂), 3.41 (t, 2H, CH₂S), 5.12 (s, 2H, OCH₂), 7.21–8.04 (m, 4H, Ar-H); ¹³C-NMR (CDCl₃): δ 25.45, 26.32, 28.17, 50.67, 55.88, 59.80, 64.53, 118.44, 129.35, 132.57, 158.21; LC-MS m/z 353 (M⁺), 355 (M+2). Anal. Calcd. for C₁₆H₂₀ClN₃O₂S: C, 54.31; H, 5.70; N, 11.87. Found: C, 54.47; H, 5.58; N, 11.59%.

2-(3-(4-Chlorophenoxy)propyl)-5-((2-(piperidin-1-yl) ethyl)thio)-1,3,4-oxadiazole (6b) Yield 73%; mp. 87-89°C; FT-IR (KBr, cm⁻¹): 1333 (C=N), 1272 (C-O-C); ¹H NMR (CDCl₃): δ 1.58 (m, 6H, 2CH₂ of piperidine ring), 2.15 (m, 2H, CH₂), 2.39 (t, 4H, CH₂NCH₂ of piperidine ring), 2.86 (t, 2H, NCH₂), 2.90 (t, 2H, CH₂), 3.35 (t, 2H, CH₂S), 3.90 (t, 2H, OCH₂), 7.27-8.11 (m, 4H, Ar-H); ¹³C-NMR (CDCl₃): δ 21.16, 26.89, 27.77, 29.99, 48.96, 59.85, 64.55, 72.46, 79.16, 118.90, 123.65, 130.78, 156.23; LC-MS m/z 381 (M⁺), 383 (M+2). Anal. Calcd. for C₁₈H₂₄ClN₃O₂S: C, 56.61; H, 6.33; N, 11.00. Found: C, 56.63; H, 6.30; N, 10.81%.

2-((3-Nitrophenoxy)methyl)-5-((2-(piperidin-1-yl)ethyl)thio)-1,3,4-oxadiazole (6c) Yield 70%; mp. 81-83°C; FT-IR (KBr, cm $^{-1}$): 1336 (C=N), 1276 (C-O-C); 1 H NMR (CDCl $_{3}$): δ 1.56 (m, 6H, 2CH $_{2}$ of piperidine ring), 2.41 (t, 4H, CH $_{2}$ NCH $_{2}$ of piperidine ring), 2.90 (t, 2H, CH $_{2}$ N), 3.53 (t, 2H, CH $_{2}$ S), 5.34 (s, 2H, OCH $_{2}$), 7.05-7.79 (m, 4H, Ar-H); 13 C-NMR (CDCl $_{3}$): δ 25.55, 26.67, 30.25, 50.57, 54.55, 68.50, 75.31, 115.84, 137.05, 154.96, 165.47; LC-MS m/z 365 (M+1). Anal. Calcd. for C $_{16}$ H $_{20}$ N $_{4}$ O $_{4}$ S: C, 52.73; H, 5.53; N, 15.37. Found: C, 52.68; H, 5.51; N, 15.38%.

2-(3-(3-Nitrophenoxy)propyl)-5-((2-(piperidin-1-yl) ethyl)thio)-1,3,4-oxadiazole (6d) Yield 76%; mp. 85-87°C; IR (cm⁻¹): 1338 (C=N), 1276 (C-O-C); ¹H NMR (CDCl₃): δ 1.57 (m, 6H, 2CH₂ of piperidine ring), 2.32 (m, 2H, CH₂), 2.40 (t, 4H, CH₂NCH₂ of piperidine ring), 2.77 (t, 2H, CH₂N), 2.95 (t, 2H, CH₂), 3.43 (t, 2H, CH₂S), 3.96 (t, 2H, OCH₂), 7.10–7.89 (m, 4H, Ar-H); ¹³C-NMR (CDCl₃): δ 22.46, 24.76, 24.54, 28.64, 53.17, 60.71, 66.92, 77.54,

116.72, 127.62, 130.78, 156.23, 166.53; LC-MS m/z 393 (M+1). Anal. Calcd. for C₁₈H₂₄N₄O₄S: C, 55.08; H, 6.16; N, 14.28. Found: C, 54.78; H, 6.11; N, 14.32%.

2-(3-(4-Bromophenoxy)propyl)-5-((2-(piperidin-1-yl) ethyl)thio)-1,3,4-oxadiazole (6e) Yield 79%; mp. 78-80°C; FT-IR (KBr, cm⁻¹): 1336 (C=N), 1276 (C-O-C); ¹H NMR (CDCl₃): δ 1.54 (m, 6H, 2CH₂ of piperidine ring), 2.22 (m, 2H, CH₂), 2.39 (t, 4H, CH₂NCH₂ of piperidine ring), 2.83 (t, 2H, CH₂N), 2.97 (t, 2H, CH₂), 3.35 (t, 2H, CH₂S), 3.93 (t, 2H, OCH₂), 7.10-7.89 (m, 4H, Ar-H); ¹³C-NMR (CDCl₃): δ 21.45, 23.12, 26.76, 30.05, 53.40, 57.66, 63.21, 72.83, 76.89, 117.52, 124.08, 156.23; LC-MS m/z 425 (M⁺), 227 (M+2). Anal. Calcd. for C₁₈H₂₄BrN₃O₂S: C, 50.71; H, 5.67; N, 9.86. Found: C, 50.66; H, 5.53; N, 9.81%.

2-((2-(Piperidin-1-yl)ethyl)thio)-5-((o-tolyloxy) methyl)-1,3,4-oxadiazole (6f) Yield 82%; mp. 74-76°C; FT-IR (KBr, cm⁻¹): 1333 (C=N), 1277 (C-O-C); ¹H NMR (CDCl₃): δ 1.56 (m, 6H, 2CH₂ of piperidine ring), 2.16 (s, 3H, CH₃), 2.35 (t, 4H, CH₂NCH₂ of piperidine ring), 2.73 (t, 2H, CH₂N), 3.44 (t, 2H, CH₂S), 5.11 (s, 2H, OCH₂), 6.97-7.54 (m, 4H, Ar-H); ¹³C-NMR (CDCl₃): δ 14.23, 23.53, 26.54, 30.99, 50.72, 53.87, 60.02, 77.53, 77.75, 114.33, 131.88, 153.39, 156.22; LC-MS m/z 334 (M+1). Anal. Calcd. for C₁₇H₂₃N₃O₂S: C, 61.23; H, 6.95; N, 12.60 Found: C, 61.27; H, 6.81; N, 12.46%.

2-((4-Methoxyphenoxy)methyl)-5-((2-(piperidin-1-yl) ethyl)thio)-1,3,4-oxadiazole (6g) Yield 75%; mp. 71-73°C; FT-IR (KBr, cm⁻¹): 1330 (C=N), 1265 (C-O-C); ¹H NMR (CDCl₃): δ 1.56 (m, 6H, 2CH₂ of piperidine ring), 2.37 (t, 4H, CH₂NCH₂ of piperidine ring), 2.83 (t, 2H, CH₂N), 3.51 (t, 2H, CH₂S), 3.86 (s, 3H, OCH₃), 5.17 (s, 2H, OCH₂), 6.92–7.21 (m, 4H, Ar-H); ¹³C-NMR (CDCl₃): δ 24.51, 26.62, 28.66, 36.89, 56.36, 66.45, 77.35, 77.35, 116.38, 119.04, 151.02, 163.12; LC-MS m/z 350 (M+1). Anal. Calcd. for C₁₇H₂₃N₃O₃S: C, 58.43; H, 6.63; N, 12.02. Found: C, 58.27; H, 6.43; N, 11.89%.

2-(3-(4-Methoxyphenoxy)propyl)-5-((2-(piperidin-1-yl)ethyl)thio)-1,3,4-oxadiazole (**6h**) Yield 72%; mp. 90–92°C; FT-IR (KBr, cm⁻¹): 1330 (C=N), 1265 (C-O-C); ¹H NMR (CDCl₃): δ 1.58 (m, 6H, 2CH₂ of piperidine ring), 2.32 (m, 2H, CH₂), 2.37 (t, 4H, CH₂NCH₂ of piperidine ring), 2.75 (t, 2H, CH₂N), 2.95 (t, 2H, CH₂), 3.43 (t, 2H, CH₂S), 3.83 (s, 3H, OCH₃), 4.16 (t, 2H, OCH₂), 6.58–7.13 (m, 4H, Ar-H); ¹³C-NMR (CDCl₃): δ 25.54, 26.32, 28.87, 30.52, 51.26, 58.43, 64.36, 76.90, 78.57, 114.66, 124.76, 132.35, 152.14, 164.17; LC-MS m/z 378 (M+1). Anal. Calcd. for C₁₉H₂₇N₃O₃S: C, 60.45; H, 7.21, N, 11.13. Found: C, 60.36; H, 7.06, N, 11.11%.

Biology; antioxidant activity assay

Compounds **6a-h** were tested for antioxidant property by DPPH, NO, and H,O, radical scavenging methods.

DPPH radical scavenging activity

The scavenging effect of 2,2'diphenyl-1-picrylhydrazyl (DPPH) radical was assessed according to earlier method. [17] 0.1 µM solution of DPPH in methanol was prepared, and 1 mL of various concentrations of the test compounds (50, 75, and 100 µg/mL) in methanol was added. The mixture

was shaken vigorously and allowed to stand at room temperature for 30 min, and the absorbance was read against blank at 517 nm. Ascorbic acid was used as the standard. The difference between the test and the control experiments was taken and expressed as the percentage scavenging of the DPPH radical as the following equation:

I%=
$$[(A_{control} - A_{sample})/A_{blank}] \times 100$$

Where I% is the percentage of inhibition, A_{control} is the absorbance of the control reaction, A_{sample} is the absorbance of the test compound, and A_{blank} is the absorbance of the blank

NO scavenging activity

NO was generated from sodium nitroprusside and measured by the Griess reaction as described previously^[18] with slight modification. Sodium nitroprusside (2M) in phosphate-buffered saline was mixed with different concentrations of the of the test compounds (50, 75, and 100 µg/mL) and incubated at 25°C for 150 min. 1 mL of the reaction mixture was treated with 1 mL of Griess reagent (1% sulfanilamide, 2% H₃PO₄, and 0.1% naphthylethylenediamine dihydrochloride). The absorbance of the chromophore formed during the diazotization of nitrite with sulfanilamide and its subsequent coupling with naphthylethylenediamine was read at 546 nm, relative to the absorbance of standard solutions of potassium nitrite treated in the same way with Griess reagent. Ascorbic acid was used as the standard. NO scavenging activity was calculated by the following equation:

$$I\% = [(A_{control} - A_{sample})/A_{blank}] \times 100$$

H₂O₂, scavenging activity

The ${\rm H_2O_2}$ radical scavenging effect of the test compound was determined according to the pervious method^[19] with slight modifications. 2 mL (800 µmol/L) of ${\rm H_2O_2}$ was prepared in phosphate buffer (pH 7.4) and mixed with 2 mL of the test compounds (50, 75, and 100 µg/mL), and the solution was incubated at room temperature for 15 min. The absorbance value of the reaction mixture was recorded at 230 nm against a blank. Ascorbic acid was used as the standard. The capability of scavenging effect on ${\rm H_2O_2}$ was calculated as follows:

$$I\% = [(A_{control} - A_{sample})/A_{blank}] \times 100$$

CONCLUSION

The oxadiazole–piperidine derivatives **6a-h** were synthesized and screened for *in vitro* antioxidant activities. Compounds **6a** and **6b** having chloro substituent in the benzene ring displayed greater radical scavenging activity while the others compounds showed moderate-to-poor radical scavenging abilities in comparison with the standard antioxidant ascorbic acid.

REFERENCES

[1] Nita, M., Grzybowski, A. The role of the reactive oxygen species and oxidative stress in the path mechanism of

- the age-related ocular diseases and other pathologies of the anterior and posterior eye segments in adults. *Oxid. Med. Cell Longev.*, **2016**, ID: 3164734.
- [2] Aboul-Enein, Y.H., Berczynski, P., Kruk, I. Phenolic compounds: The role of redox regulation in neurodegenerative disease and cancer. *Mini. Rev. Med. Chem.*, **2013**, *1*, 385-398.
- [3] Evans, M.D., Dizdaroglu, M., Cooke, M.S. Oxidative DNA damage and disease: Induction, repair and significance. *Mutat. Res. Rev. Mutat. Res.*, 2004, 567, 1-61.
- [4] Shaikh, A., Meshram, J. Novel 1,3,4-oxadiazole derivatives of dihydropyrimidinones: Synthesis, anti-inflammatory, anthelmintic, and antibacterial activity evaluation. *J. Heterocycl. Chem.*, **2016**, *53*, 1176-1182.
- [5] Husain, A., Ajmal, M. Synthesis of novel 1,3,4-oxadiazole derivatives and their biological properties. *Acta Pharm.*, 2009, 59, 223-233.
- [6] Zarghi, A., Tabatabai, S.A., Faizi, M., Ahadian, A., Navabi, P., Zanganeh, V., Shafiee, A. Synthesis and anticonvulsant activity of new 2substituted-5-(2benzyloxyphenyl)-1, 3, 4-oxadiazoles. *Bioorg. Med. Chem. Lett.*, 2005, 15, 1863-1865.
- [7] Al-Ghorbani, M., Vigneshwaran, V., Ranganatha, V.L., Prabhakar, B.T., Khanum, S. A. Synthesis of oxadiazole–morpholine derivatives and manifestation of the repressed CD31 microvessel density (MVD) as tumoral angiogenic parameters in Dalton's Lymphoma. *Bioorg. Chem.*, 2015, 60, 136–146.
- [8] Leal, J.G., Sauer, A.C., Mayer, J.C.P., Stefanello, S.T., Gonçalves, D.F., Soares, F.A.A., Iglesias, B.A., Back, D.F., Oscar E.D. Rodrigues and Luciano Dornelles. synthesis and electrochemical and antioxidant properties of chalcogenocyanate oxadiazole and5heteroarylchalcogenomethyl-1H-tetrazole derivatives. New J. Chem., 2017, 41, 5875-5883.
- [9] Gobec, M., Tomas'ic', T., Markovic', T., Mlinaric'-Ras'c'an, I., Dolenc M.S., Jakopin, Z'. Antioxidant and anti-inflammatory properties of 1,2,4-oxadiazole analogs of resveratrol. *Chem. Biol. Interact.*, 2015, 240, 200-207.

- [10] Kotaiah, Y., Harikrishna, N., Nagaraju, K., Rao, C.V. Synthesis and antioxidant activity of 1,3,4-oxadiazole tagged thieno[2,3-d]pyrimidine derivatives. Eur. J. Med. Chem., 2012, 58, 340-345.
- [11] Mohana, K.N., Kumar C.B.P. Synthesis and antioxidant activity of 2-Amino-5-methylthiazol derivatives containing 1,3,4-oxadiazole-2-thiol moiety. *ISRN Org. Chem.*, **2013**, Article ID 620718, 8.
- [12] Menteşe, E., Ülker, S., Kahveci. B. Synthesis and study of α-glucosidase inhibition, antimicrobial and antioxidant activities of some benzimidazole derivatives containing triazole, thiadiazole, oxadiazole, and morpholine rings. Heterocyclic. Chem. 2014, 12 1820-1831.
- [13] Kim, J.H., Shyam, P.K., Kim, M.J., Lee, H., Lee, J.T., Jang, H.Y. Enantioselective synthesis and antioxidant activity of 3,4,5-substituted piperidine derivatives. *Bioorg. Med. Chem. Lett.*, **2016**, *26*, 3119-3121.
- [14] Prashanth, M.K., Revanasiddappa, D.H., Rai, K.M.L., Veeresh, B. Synthesis, characterization, antidepressant and antioxidant activity of novel piperamides bearing piperidine and piperazine analogues. *Bioorg. Med. Chem. Lett.*, 2012, 22, 7065-70.
- [15] Abou-Gharbi, M., Moyer, J.A., Nielsen, S.T., Webb, M., Patel, U. New antihistamines: Substituted piperazine and piperidine derivatives as novel H1-antagonists, *J. Med. Chem.*, 1995, 38, 4026–4032.
- [16] Arslan, S., Loğoğlu, E., Oktemer. A. Antimicrobial activity studies on some piperidine and pyrrolidine substituted halogenobenzene derivatives. J. Enzyme Inhib. Med. Chem. 2006, 21, 211-214.
- [17] Burits, M., Bucar, F. Antioxidant activity of Nigella sativa essential oil. *Phytother. Res.*, **2000**, *14*, 323–328.
- [18] Marcocci, L., Maguire, J.J., Droy-Lefaix, M.T., Packer, L. The nitric oxide-scavenging properties of Ginkgo biloba extract EGb 761. Biochem. Biophys. Res. Commun., 1994, 201, 748–755.
- [19] Ruch R.J., Cheng S.J., Klaunig J.E. Prevention of cytotoxicity and inhibition of intercellular communication by antioxidant catechins isolated from Chinese green tea. *Carcinogenesis*, 1989, 10, 1003–1008.

Received: 16 Feb 2018; Accepted: 13 Jun 2018